Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors

Hui-Rong Jiang, David E Gilham, Kate Mulryan, Natalia Kirillova, Robert E Hawkins, Peter L Stern

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We have generated murine T cells expressing chimeric immune receptors (CR) against human 5T4 oncofetal Ag (h5T4) and evaluated their tumor therapeutic efficacy alone and in combination with immunization using a replication-defective adenovirus encoding h5T4 (Rad.h5T4) and bone marrow-derived dendritic cells (BMDC). The h5T4-specific engineered T cells demonstrated Ag-specific, non-MHC-restricted cytolysis of h5T4-positive B16 and CT26 tumor cells in vitro by cytotoxicity assay and antitumor activity in vivo using a Winn assay. In the s.c. injected B16h5T4 melanoma model, early local but not systemic i.v. administration of syngeneic h5T4-specific CR T cells significantly increased mice survival. This improvement was further enhanced when combined with immunization with Rad.h5T4, followed by post-CR T cell treatment with BMDC in the active therapy model, possibly through mechanisms of enhancing Ag-specific cellular immune responses. This synergistic effect was lost without delivery of the BMDC. Our findings suggest that combining engineered T cells with specific vaccination strategies can improve the active tumor therapy.

LanguageEnglish
Pages4288-4298
Number of pages11
JournalJournal of Immunology
Volume177
Issue number7
DOIs
Publication statusPublished - 1 Oct 2006

Fingerprint

T-Cell Antigen Receptor
Vaccination
Dendritic Cells
Bone Marrow
T-Lymphocytes
Adenoviridae
Immunization
Neoplasms
Therapeutics
Cellular Immunity
Melanoma

Keywords

  • adenoviridae
  • adoptive transfer
  • cancer vaccines

Cite this

Jiang, Hui-Rong ; Gilham, David E ; Mulryan, Kate ; Kirillova, Natalia ; Hawkins, Robert E ; Stern, Peter L. / Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. In: Journal of Immunology . 2006 ; Vol. 177, No. 7. pp. 4288-4298.
@article{56ef399d0ef34bba9a1e2c2aa6fa8314,
title = "Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors",
abstract = "We have generated murine T cells expressing chimeric immune receptors (CR) against human 5T4 oncofetal Ag (h5T4) and evaluated their tumor therapeutic efficacy alone and in combination with immunization using a replication-defective adenovirus encoding h5T4 (Rad.h5T4) and bone marrow-derived dendritic cells (BMDC). The h5T4-specific engineered T cells demonstrated Ag-specific, non-MHC-restricted cytolysis of h5T4-positive B16 and CT26 tumor cells in vitro by cytotoxicity assay and antitumor activity in vivo using a Winn assay. In the s.c. injected B16h5T4 melanoma model, early local but not systemic i.v. administration of syngeneic h5T4-specific CR T cells significantly increased mice survival. This improvement was further enhanced when combined with immunization with Rad.h5T4, followed by post-CR T cell treatment with BMDC in the active therapy model, possibly through mechanisms of enhancing Ag-specific cellular immune responses. This synergistic effect was lost without delivery of the BMDC. Our findings suggest that combining engineered T cells with specific vaccination strategies can improve the active tumor therapy.",
keywords = "adenoviridae, adoptive transfer, cancer vaccines",
author = "Hui-Rong Jiang and Gilham, {David E} and Kate Mulryan and Natalia Kirillova and Hawkins, {Robert E} and Stern, {Peter L}",
year = "2006",
month = "10",
day = "1",
doi = "10.4049/jimmunol.177.7.4288",
language = "English",
volume = "177",
pages = "4288--4298",
journal = "Journal of Immunology",
issn = "0022-1767",
number = "7",

}

Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. / Jiang, Hui-Rong; Gilham, David E; Mulryan, Kate; Kirillova, Natalia; Hawkins, Robert E; Stern, Peter L.

In: Journal of Immunology , Vol. 177, No. 7, 01.10.2006, p. 4288-4298.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors

AU - Jiang, Hui-Rong

AU - Gilham, David E

AU - Mulryan, Kate

AU - Kirillova, Natalia

AU - Hawkins, Robert E

AU - Stern, Peter L

PY - 2006/10/1

Y1 - 2006/10/1

N2 - We have generated murine T cells expressing chimeric immune receptors (CR) against human 5T4 oncofetal Ag (h5T4) and evaluated their tumor therapeutic efficacy alone and in combination with immunization using a replication-defective adenovirus encoding h5T4 (Rad.h5T4) and bone marrow-derived dendritic cells (BMDC). The h5T4-specific engineered T cells demonstrated Ag-specific, non-MHC-restricted cytolysis of h5T4-positive B16 and CT26 tumor cells in vitro by cytotoxicity assay and antitumor activity in vivo using a Winn assay. In the s.c. injected B16h5T4 melanoma model, early local but not systemic i.v. administration of syngeneic h5T4-specific CR T cells significantly increased mice survival. This improvement was further enhanced when combined with immunization with Rad.h5T4, followed by post-CR T cell treatment with BMDC in the active therapy model, possibly through mechanisms of enhancing Ag-specific cellular immune responses. This synergistic effect was lost without delivery of the BMDC. Our findings suggest that combining engineered T cells with specific vaccination strategies can improve the active tumor therapy.

AB - We have generated murine T cells expressing chimeric immune receptors (CR) against human 5T4 oncofetal Ag (h5T4) and evaluated their tumor therapeutic efficacy alone and in combination with immunization using a replication-defective adenovirus encoding h5T4 (Rad.h5T4) and bone marrow-derived dendritic cells (BMDC). The h5T4-specific engineered T cells demonstrated Ag-specific, non-MHC-restricted cytolysis of h5T4-positive B16 and CT26 tumor cells in vitro by cytotoxicity assay and antitumor activity in vivo using a Winn assay. In the s.c. injected B16h5T4 melanoma model, early local but not systemic i.v. administration of syngeneic h5T4-specific CR T cells significantly increased mice survival. This improvement was further enhanced when combined with immunization with Rad.h5T4, followed by post-CR T cell treatment with BMDC in the active therapy model, possibly through mechanisms of enhancing Ag-specific cellular immune responses. This synergistic effect was lost without delivery of the BMDC. Our findings suggest that combining engineered T cells with specific vaccination strategies can improve the active tumor therapy.

KW - adenoviridae

KW - adoptive transfer

KW - cancer vaccines

U2 - 10.4049/jimmunol.177.7.4288

DO - 10.4049/jimmunol.177.7.4288

M3 - Article

VL - 177

SP - 4288

EP - 4298

JO - Journal of Immunology

T2 - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -